Nidanilimab

Products

Quote Request

Catalog No.: PC0076

Size: 1 mg,5 mg, 10 mg, 50mg, 100 mg

Description

Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumor cells. Nidanilimab can be used in the research of non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).

CAS No.	2171061-85-9
Appearance	Liquid
Color	Colorless to light yellow
Shipping	Shipping with dry ice.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
*In Vitro*	Nidanilimab (CAN04; 20 µg/mL; murine MC38 colon cancer cells) has glycoengineered to mediate an enhanced antibody-dependent cellular cytotoxicity (ADCC, EC50<1 nM). Nidanilimab (20 µg/mL; murine MC38 colon cancer cells) blocks IL1α and IL1β signaling with IC₅₀ values of 3.9 nM and 4.1 nM, respectively.
*In Vivo*	Nidanilimab (CAN04; 10 mg/kg; i.p.; nude C57Bl/6 mice) increases the efficacy of Cisplatin (HY-17394)/Gemcitabine (HY-17026) and Carboplatin (HY-17393)/Gemcitabine (HY-17026), two commonly used platinum-based chemotherapies.

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.